London, UK (PRWEB) August 20, 2012
One of the most crucial aspects of growth strategy for a generic company or an active pharmaceutical ingredient (API) manufacturing company is product selection.
New research study “Prioritizing Generic Drug development pipeline – The top Fifty Opportunities” developed by MP Advisors has been recently published by Market Publishers Ltd.
Title: Prioritizing Generic Drug development pipeline – The top Fifty Opportunities
Published: June, 2012
Price: US$ 5,000.00
The research study essentially drills down to 50 drugs, whose peak sales potential is in excess of USD 500 million by the time they reach their patent expiries. The Top 50 Para IV opportunities are structured into 5 tiers, with Top 10 opportunities classified as Tier 1.
The report offers a detailed description of the Tier 1 opportunities, provides a summary description of Tier 2 products and a list for rest of the products structured as Tier 3, 4 and 5 based on their significance. The cumulative sales potential of the top 10 drugs discussed exceeds USD 25 billion, while due to the impact of therapeutic substitution, post patent expiry should the volume should go up. The Top 50 molecules are either recently approved or are in late stage development / filed but with significantly success probability (>90%).
The products selected span across four therapy areas:
- infectious disease
- central nervous system
- metabolic disorders
More new research studies by the publisher can be found at MP Advisors page.